Prognostic factors and early risk-adapted therapy in patients with chronic lymphocytic leukemia in Binet stage A
Not Applicable
Completed
- Conditions
- Chronic Lymphocytic Leukemia (CLL) Binet stage A, untreatedCancerLymphoid leukaemia
- Registration Number
- ISRCTN31378214
- Lead Sponsor
- German CLL Study Group (GCLLSG) (Germany)
- Brief Summary
2020 results in https://www.ncbi.nlm.nih.gov/pubmed/32042081 (added 12/02/2020)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 539
Inclusion Criteria
1. Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) in Binet stage A
2. Initial diagnosis within the last three years
3. No previous therapy
4. Age between 18 and 75 years
5. Eastern Cooperative Oncology Group (ECOG) status zero to two
6. Signed informed consent
Exclusion Criteria
1. Autoimmune cytopenia
2. Severe concommitant disease
3. Concomitant secondary neoplasia
4. Participation in another clinical trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival
- Secondary Outcome Measures
Name Time Method <br> 1. Overall survival<br> 2. Quality of life<br> 3. Incidence of infections<br>